Jeff Dunn1,2,3,4, Maggie Watson5, Joanne F Aitken1,2,4,6, Melissa K Hyde1,2. 1. Cancer Council Queensland, Brisbane, Queensland, Australia. 2. Menzies Health Institute Queensland, Griffith University, Gold Coast, Queensland, Australia. 3. School of Social Science, The University of Queensland, St Lucia, Queensland, Australia. 4. Institute for Resilient Regions, University of Southern Queensland, Toowoomba, Australia. 5. Pastoral and Psychological Care, Royal Marsden Hospital, Sutton, Surrey, UK. 6. School of Public Health and Social Work, Queensland University of Technology, Brisbane, Queensland, Australia.
Abstract
BACKGROUND: New advanced melanoma therapies are associated with improved survival; however, quality of survivorship, particularly psychosocial outcomes, for patients overall and those treated with newer therapies is unclear. OBJECTIVE: Synthesize qualitative and quantitative evidence about psychosocial outcomes for advanced (stage III/IV) melanoma patients. METHODS: Five databases were searched (01/01/1980 to 31/01/2016). Inclusion criteria were as follows: advanced melanoma patients or sub-group analysis; assessed psychosocial outcomes; and English language. RESULTS: Fifty-two studies met review criteria (4 qualitative, 48 quantitative). Trials comprise mostly medical not psychosocial interventions, with psychosocial outcomes assessed within broader quality of life measures. Patients receiving chemotherapy or IFN-alpha showed decreased emotional and social function and increased distress. Five trials of newer therapies appeared to show improvements in emotional and social function. Descriptive studies suggest that patients with advanced, versus localized disease, had decreased emotional and social function and increased distress. Contributors to distress were largely unexplored, and no clear framework described coping/adjustment trajectories. Patients with advanced versus localized disease had more supportive care needs, particularly amount, quality, and timing of melanoma-related information, communication with and emotional support from clinicians. Limitations included: lack of theoretical underpinnings guiding study design; inconsistent measurement approaches; small sample sizes; non-representative sampling; and cross-sectional design. CONCLUSIONS: Quality trial evidence is needed to clarify the impact of treatment innovations for advanced melanoma on patients' psychosocial well-being. Survivorship research and subsequent translation of that knowledge into programs and services currently lags behind gains in the medical treatment of advanced melanoma, a troubling circumstance that requires immediate and focused attention.
BACKGROUND: New advanced melanoma therapies are associated with improved survival; however, quality of survivorship, particularly psychosocial outcomes, for patients overall and those treated with newer therapies is unclear. OBJECTIVE: Synthesize qualitative and quantitative evidence about psychosocial outcomes for advanced (stage III/IV) melanomapatients. METHODS: Five databases were searched (01/01/1980 to 31/01/2016). Inclusion criteria were as follows: advanced melanomapatients or sub-group analysis; assessed psychosocial outcomes; and English language. RESULTS: Fifty-two studies met review criteria (4 qualitative, 48 quantitative). Trials comprise mostly medical not psychosocial interventions, with psychosocial outcomes assessed within broader quality of life measures. Patients receiving chemotherapy or IFN-alpha showed decreased emotional and social function and increased distress. Five trials of newer therapies appeared to show improvements in emotional and social function. Descriptive studies suggest that patients with advanced, versus localized disease, had decreased emotional and social function and increased distress. Contributors to distress were largely unexplored, and no clear framework described coping/adjustment trajectories. Patients with advanced versus localized disease had more supportive care needs, particularly amount, quality, and timing of melanoma-related information, communication with and emotional support from clinicians. Limitations included: lack of theoretical underpinnings guiding study design; inconsistent measurement approaches; small sample sizes; non-representative sampling; and cross-sectional design. CONCLUSIONS: Quality trial evidence is needed to clarify the impact of treatment innovations for advanced melanoma on patients' psychosocial well-being. Survivorship research and subsequent translation of that knowledge into programs and services currently lags behind gains in the medical treatment of advanced melanoma, a troubling circumstance that requires immediate and focused attention.
Authors: Winson Y Cheung; Martha S Bayliss; Michelle K White; Angela Stroupe; Andrew Lovley; Bellinda L King-Kallimanis; Kathryn Lasch Journal: Support Care Cancer Date: 2018-01-10 Impact factor: 3.603
Authors: Natalia Ziolkowski; Simon C Kitto; Dahn Jeong; Jennifer Zuccaro; Thomasin Adams-Webber; Anna Miroshnychenko; Joel S Fish Journal: BMJ Open Date: 2019-06-03 Impact factor: 2.692
Authors: Evie E M Kolsteren; Esther Deuning-Smit; Judith B Prins; Winette T A van der Graaf; Carla M L van Herpen; Sophie Lebel; Belinda Thewes; Linda Kwakkenbos; José A E Custers Journal: BMJ Open Date: 2021-01-31 Impact factor: 2.692
Authors: Alessandro Borghi; Maria Elena Flacco; Alberto Monti; Lucrezia Pacetti; Michela Tabanelli; Monica Corazza Journal: Support Care Cancer Date: 2022-01-15 Impact factor: 3.359
Authors: Julia Lai-Kwon; Brooke Kelly; Sarah Lane; Rebecca Biviano; Iris Bartula; Frank Brennan; Ingrid Kivikoski; Jake Thompson; Haryana M Dhillon; Alexander Menzies; Georgina V Long Journal: Support Care Cancer Date: 2022-09-22 Impact factor: 3.359
Authors: Evie E M Kolsteren; Esther Deuning-Smit; Alanna K Chu; Yvonne C W van der Hoeven; Judith B Prins; Winette T A van der Graaf; Carla M L van Herpen; Inge M van Oort; Sophie Lebel; Belinda Thewes; Linda Kwakkenbos; José A E Custers Journal: Cancers (Basel) Date: 2022-08-11 Impact factor: 6.575
Authors: Anne Rogiers; Christophe Leys; Justine Lauwyck; Adrian Schembri; Gil Awada; Julia Katharina Schwarze; Jennifer De Cremer; Peter Theuns; Paul Maruff; Mark De Ridder; Jan L Bernheim; Bart Neyns Journal: J Immunol Res Date: 2020-07-21 Impact factor: 4.818
Authors: Winson Y Cheung; Michelle K White; Martha S Bayliss; Angela Stroupe; Andrew Lovley; Bellinda L King-Kallimanis; Kathryn Lasch Journal: Support Care Cancer Date: 2018-06-23 Impact factor: 3.603